The risk of dyspnea in patients treated with third-generation P2Y(12) inhibitors compared with clopidogrel: a meta-analysis of randomized controlled trials

BACKGROUND: Ticagrelor and prasugrel are two third-generation oral P2Y(12) inhibitors which are more commonly used in clinical practice. However, dyspnea has been consecutively reported in patients using third-generation oral P2Y(12) inhibitors. This study aims to compare the risk of dyspnea in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Na, Xu, Weisen, Li, Ou, Zhang, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079377/
https://www.ncbi.nlm.nih.gov/pubmed/32183711
http://dx.doi.org/10.1186/s12872-020-01419-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079377/
https://www.ncbi.nlm.nih.gov/pubmed/32183711
http://dx.doi.org/10.1186/s12872-020-01419-y

Ejemplares similares